Company Ind-Swift Laboratories Limited

INDSWFTLAB

INE915B01019

Pharmaceuticals

Market Closed - NSE India S.E. 11:22:04 30/10/26 pm AEDT			5-day change	1st Jan Change
368.20 ^INR	-10.15%		+6.62%	+317.70%

29/10	Ind-Swift Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
06/10	Ind-Swift Laboratories Limited Approves Appointment of Amit Mathur as Independent Director	CI

Business description: Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Companyâ€™s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.

Number of employees: 1,388

Sales by Activity: Ind-Swift Laboratories Limited

Fiscal Period: March	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)	2026 (INR)
Pharmaceutical Business	10.52B	12.16B	12.97B	5.62B	6.49B

See all business segments

Geographical breakdown of sales: Ind-Swift Laboratories Limited

Fiscal Period: March	2022 (INR)	2023 (INR)	2024 (INR)	2025 (INR)	2026 (INR)
Export	7.96B	9.37B	10.02B	4.06B	4.94B
India	2.43B	2.7B	2.79B	1.56B	1.32B

See all geographic segments

Executive Committee: Ind-Swift Laboratories Limited

Manager	Title	Age	Since
Sahil Munjal CEO	Chief Executive Officer	46	-
Himanshu Jain CEO	Chief Executive Officer	44	15/06/2011
Gagan Aggarwal DFI	Director of Finance/CFO	-	29/09/2018
Ashok Kothari CTO	Chief Tech/Sci/R&D Officer	-	01/04/2017
Pardeep Verma CMP	Compliance Officer	-	11/10/2012

See IND-SWIFT LABORATORIES LIMITED governance

Composition of the Board of Directors: Ind-Swift Laboratories Limited

Director	Title	Age	Since
Himanshu Jain BRD	Director/Board Member	44	-
Navrattan R. Munjal CHM	Chairman	74	-
Rishav Mehta BRD	Director/Board Member	35	23/03/2010
Neerja Chathley BRD	Director/Board Member	71	10/05/2019
Sahil Munjal BRD	Director/Board Member	46	13/02/2020
Rajinder Kumar Gupta BRD	Director/Board Member	70	23/06/2021
Subodh Gupta BRD	Director/Board Member	-	05/07/2025

Composition of the Board of Directors

Shareholders: Ind-Swift Laboratories Limited

Name	Stocks	%	Valuation
IND-SWIFT LABORATORIES LIMITED 39.42 %	34,282,521	39.42 %	138 M ₹
Zeal Asset Management Ltd. 4.615 %	4,013,561	4.615 %	16 M ₹
Nova Global Opportunities Fund Pcc - Touchstone 3.242 %	2,819,256	3.242 %	11 M ₹
Panchkula Finvest Pvt Ltd. 2.478 %	2,155,169	2.478 %	9 M ₹
Ashok Kumar Chandak 2.394 %	2,082,291	2.394 %	8 M ₹

List of IND-SWIFT LABORATORIES LIMITED shareholders

Holdings: Ind-Swift Laboratories Limited

Name	Stocks	%	Valuation
IND-SWIFT LABORATORIES LIMITED 39.42%	34,282,521	39.42%	138 M $

Company details: Ind-Swift Laboratories Limited

Ind-Swift Laboratories Ltd.

SCO 850, Shivalik Enclave

160101, Manimajra

+91 17 2506 1850

http://www.indswiftlabs.com

address Ind-Swift Laboratories Limited(INDSWFTLAB)

Generic Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IND-SWIFT LABORATORIES LIMITED	-10.15%	+6.62%	+257.37%	+331.40%	374M
ELI LILLY AND COMPANY	+3.19%	+8.48%	+74.25%	+153.03%	1,224B
JOHNSON & JOHNSON	-0.73%	+2.09%	+46.41%	+87.64%	662B
ABBVIE INC.	+1.41%	+3.40%	+30.98%	+112.26%	514B
ROCHE HOLDING AG	+0.42%	+2.88%	+54.92%	+69.67%	388B
MERCK & CO., INC.	+2.18%	+1.55%	+72.70%	+45.42%	361B
NOVARTIS AG	+1.12%	+3.80%	+35.82%	+59.72%	302B
ASTRAZENECA PLC	+6.96%	+7.55%	+11.15%	+37.89%	271B
AMGEN INC.	+1.15%	+4.19%	+59.72%	+78.16%	249B
GILEAD SCIENCES, INC.	+3.06%	+8.58%	+44.03%	+122.76%	205B
Average	+0.66%	+4.20%	+68.73%	+109.79%	417.72B
Weighted average by Cap.	+1.28%	+3.04%	+53.37%	+100.44%